SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
World game at war: why some European nations have threatened a World Cup boycott 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
NEW YORK, April 20, 2018 -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) related to its proposed initial public offering. The number of shares of stock and the price range for the proposed offering have not yet been determined. The proposed offering is subject to, among other things, completion of SEC review process and market conditions.
This press release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Contacts:
Caelum Biosciences, Inc.
Michael Spector, President & Chief Executive Officer
(212) 574-2811
[email protected]
Laura Bagby, Media Relations
6 Degrees
(312) 448-8098
[email protected]
